Thalidomide for systemic capillary leak syndrome [4]

American Journal of Medicine

Volumn 115, Issue 4, 2003, Pages 332-334

  Staak, Jan Oliver ^a   Glossmann, Jan Peter ^a   Esser, Johannes Markus ^a   Diehl, Volker ^a   Mietz, Holger ^a   Josting, Andreas ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE;

ADULT; CAPILLARY LEAK SYNDROME; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; HUMAN; LABORATORY TEST; LETTER; MALE; PATHOGENESIS; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0042880757     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(03)00349-8     Document Type: Letter

References (10)

1. Teelucksingh S., Padfield P.L., Edwards C.R. Systemic capillary leak syndrome. QJM. 75:1990;515-524.
2. Clarkson B., Thompson D., Horwith M., Luckey H.E. Cyclical edema and shock due to increased capillary permeability. Am J Med. 29:1960;193-216.
3. Zhang W., Ewan P.W., Lachmann P.J. The paraproteins in systemic capillary leak syndrome. Clin Exp Immunol. 93:1993;424-429.
4. Fellows I.W., Powell R.J., Toghill P.J., et al. Epoprostenol in systemic capillary leak syndrome [correspondence]. Lancet. 2:1988;1143.
5. Amoura Z., Papo T., Ninet J., et al. Systemic capillary leak syndrome: report on 13 patients with special focus on course and treatment. Am J Med. 103:1997;514-519.
6. Droder R.M., Kyle R.A., Greipp P.R. Control of systemic capillary leak syndrome with aminophylline and terbutaline. Am J Med. 92:1992;523-526.
7. Rondeau E., Sraer J., Bens M., et al. Production of 5-lipoxygenase pathway metabolites by peripheral leucocytes in capillary leak syndrome (Clarkson disease). Eur J Clin Invest. 17:1987;53-57.
8. Cicardi M., Gardinali M., Bisiani G., et al. The systemic capillary leak syndrome appearance of interleukin-2-receptor-positive cells during attacks . Ann Intern Med. 113:1990;475-477.
9. Brett J., Gerlach H., Nawroth P., et al. Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins. J Exp Med. 169:1989;1977-1991.
10. Sampaio E.P., Sarno E.N., Galilly R., et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 173:1991;699-703.